## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($87.77)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Amundi Sells 401,103 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251209T083506 | Neutral | Relevance: 99%
- Amundi significantly reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by selling 401,103 shares, decreasing its holdings by 38.7% in the second quarter. Despite this, other institutional investors have increased their positions in the medical equipment provider. Analysts currently rate Zimmer Biomet with a consensus "Hold" and a target price of $109.00.

**2. Zimmer Biomet Stock: Is ZBH Underperforming the Health Care Sector?**
- Source: Barchart.com | 20251210T095813 | Neutral | Relevance: 98%
-  Zimmer Biomet Holdings, Inc. (ZBH) is underperforming the Health Care Select Sector SPDR Fund (XLV) and rival Penumbra, Inc. (PEN), with its stock declining significantly from its 52-week high. Despite a positive Q3 adjusted EPS, the company's net sales fell short of consensus, contributing to its "Hold" rating from analysts. The stock has shown intense volatility, dipping below key moving averages.

**3. California Public Employees Retirement System Has $60.75 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251210T095913 | Neutral | Relevance: 97%
- The California Public Employees Retirement System significantly increased its stake in Zimmer Biomet Holdings, Inc., boosting its holdings by 107.9% to 666,049 shares, valued at $60.75 million. Other institutional investors, including Ameriprise Financial Inc. and Dodge & Cox, also made substantial changes to their positions in the medical equipment provider. Zimmer Biomet recently reported robust quarterly earnings, surpassing analyst estimates, and has provided positive guidance for FY 2025.

**4. Zimmer Biomet Stock: Is ZBH Underperforming the Health Care Sector?**
- Source: Markets Financial Content | 20251210T045500 | Neutral | Relevance: 97%
- Zimmer Biomet Holdings, Inc. (ZBH) is a large-cap medical technology company specializing in orthopedic implants. The company's stock has underperformed the Health Care Select Sector SPDR Fund (XLV) over various periods, including a 12.7% decline year-to-date compared to XLV's 9% gain. ZBH also lags behind competitor Penumbra, Inc. (PEN) and analysts currently rate ZBH as a "Hold" with an 11.3% upside to the mean price target.

**5. Citigroup Adjusts Price Target on Zimmer Biomet Holdings to $94 From $98, Maintains Neutral Rating**
- Source: marketscreener.com | 20251211T123150 | Neutral | Relevance: 91%
-  Citigroup has revised its price target for Zimmer Biomet Holdings (ZBH) to $94, down from $98, while upholding a Neutral rating on the stock. This adjustment reflects Citigroup's latest analysis of the medical equipment company. The article also lists other recent analyst adjustments and news pertaining to Zimmer Biomet Holdings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 6.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Forward P/E 10.9x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.3B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 10.9 |
| Current P/E | 11.3 |
| YoY Growth | 4.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.2% to -2.4% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.42% (CS: 26) | Weak |
| RSI_14 | 45.4 | Neutral |
| MACD Histogram | 0.12 | Bullish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.937x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $92.45
- **Stop Loss:** $87.77 (5.1% risk)
- **Target:** $101.81 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 294
- **Position Value:** $27,180.30
- **Portfolio %:** 27.18%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*